-
Mashup Score: 3FDA Issues CRL for Sotagliflozin in Type 1 Diabetes and CKD - 1 day(s) ago
The FDA’s decision not to approve sotagliflozin as an adjunct in T1D and CKD comes less than 2 months after a negative advisory committee meeting for the application.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0
The ATEV therapy, named Symvess, provides revascularization when autologous vein graft or implantation of a synthetic graft is not feasible.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
The FDA has approved Symvess, an acellular tissue engineered vessel-tyod therapy for treating extremity vascular trauma and preventing limb loss. Read more: https://t.co/OrFev0CGAZ
-
-
Mashup Score: 0Study Highlights Necessity of Image Quality for Deep Learning Model Diagnostic Success - 2 day(s) ago
These data resulted from an investigation of the effect of varying image qualities on the diagnostic abilities of a convolutional neural network (CNN) model and clinicians.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
In a new study, dermatologists outperformed deep learning models in binary classification with low-quality images, but the model excelled in multi-class classification with high-quality images. 🖥️ View our summary 👇 https://t.co/9AADnnwvCq #dermatology #ArtificialIntelligence
-
-
Mashup Score: 1
These findings, from an observational study, should be confirmed in a randomized, controlled trial.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
A new study found that prophylactic colchicine reduced #cardiovascular event risk in gout patients initiating urate-lowering therapy. Read more now: https://t.co/eFSSDxRmSZ
-
-
Mashup Score: 1
Submission of the Biologics License Application seeks approval of lerodalcibep to lower LDL-C in patients with or at risk for ASCVD and primary hyperlipidemia.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
LIB Therapeutics Inc. has announced the submission of a Biologics License Application (BLA) to the #FDA for lerodalcibep for reducing LDL-C in patients with ASCVD and primary hyperlipidemia. 🔗https://t.co/qDJFEhXRaK #Cardiology #FDANews #Lipids https://t.co/YYF9mEtAuV
-
-
Mashup Score: 0Study Highlights Interim Results on Abrocitinib for Adolescents, Adults with Atopic Dermatitis - 2 day(s) ago
These interim data resulted from the JADE REAL study, with 72-week results suggesting rapid improvements in eczema severity for adults and adolescents.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
#Abrocitinib treatment of atopic dermatitis led to rapid improvements in disease severity, new findings suggest, and this was maintained up to the 72-week mark in patients for whom approved systemic drugs were inadequate. View our summary here: https://t.co/OY0XAAAwCf
-
-
Mashup Score: 0Comorbidities, Social Determinants of Health Influence Hidradenitis Suppurativa, Study Finds - 2 day(s) ago
Study findings suggest an interplay between social determinants of health and HS, especially among underrepresented patient populations.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
Study findings highlight a significant interplay between social determinants of health and #hidradenitis suppurativa, additionally emphasizing notable psychosocial implications among underrepresented groups. Learn more: https://t.co/8cU3Tyk3bN
-
-
Mashup Score: 0Examining Key Aspects of Colorectal Cancer Screening: A Path to Preventing Late-Stage Cancer - 2 day(s) ago
Vivek Kaul, MD, discusses how effective colorectal cancer screening is crucial for preventing late-stage disease, highlightsing current guidelines and, available screening options, and talks about the importance of patient communication in the decision-making process.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
Vivek Kaul, MD, emphasizes the importance of colorectal cancer screening in preventing late-stage disease, covering current guidelines, available options, and the role of patient communication in decision-making. https://t.co/qQJHdx8uNG https://t.co/1fBibVkAGW
-
-
Mashup Score: 0Tralokinumab Effectively Treats Moderate-to-Severe Atopic Dermatitis: Real-World Data - 2 day(s) ago
In a recent study, tralokinumab demonstrates effectiveness and safety for treating moderate-to-severe atopic dermatitis in adults who are dupilumab naïve and non-naïve.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
Real-world data shows the 28-week efficacy of tralokinumab for moderate-to-severe #AtopicDermatitis in adults who were both previously exposed and not exposed to dupilumab. https://t.co/D9vdhwQRcg
-
-
Mashup Score: 2From LDL-C to Lp(a): A Multispecialty Approach to Reducing the Rising Tide of Cardiovascular Disease - 2 day(s) ago
Panelists discuss how comprehensive cardiovascular disease management requires integrating screening protocols, risk assessment, and targeted interventions across the lifespan, from pediatric lipid testing through adult treatment strategies, while addressing barriers to care and leveraging both established and emerging therapeutic options.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
Experts review practical approaches for treatment and prevention of cardiovascular disease in our peer-to-peer panel discussion. Watch now: https://t.co/MQBCeERj61 https://t.co/OmKiy1UpkP
-
The US Food and Drug Administration has issued a Complete Response Letter to Lexicon Pharmaceuticals for sotagliflozin (Zynquista) as an adjunct to insulin in type 1 diabetes and chronic kidney disease. https://t.co/t7AKelVEaa #Type1Diabetes #ChronicKidneyDisease